- Home
- DSP vs ATAI Comparison
DSP vs ATAI Comparison
Compare DSP & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- ATAI
- Stock Information
- Founded
- DSP 1999
- ATAI 2018
- Country
- DSP United States
- ATAI Germany
- Employees
- DSP N/A
- ATAI N/A
- Industry
- DSP EDP Services
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- ATAI Health Care
- Exchange
- DSP Nasdaq
- ATAI Nasdaq
- Market Cap
- DSP 291.3M
- ATAI 282.6M
- IPO Year
- DSP 2021
- ATAI 2021
- Fundamental
- Price
- DSP $14.39
- ATAI $1.41
- Analyst Decision
- DSP Strong Buy
- ATAI Strong Buy
- Analyst Count
- DSP 8
- ATAI 3
- Target Price
- DSP $21.75
- ATAI $10.50
- AVG Volume (30 Days)
- DSP 273.0K
- ATAI 1.4M
- Earning Date
- DSP 05-06-2025
- ATAI 05-19-2025
- Dividend Yield
- DSP N/A
- ATAI N/A
- EPS Growth
- DSP N/A
- ATAI N/A
- EPS
- DSP 0.13
- ATAI N/A
- Revenue
- DSP $306,484,000.00
- ATAI $308,000.00
- Revenue This Year
- DSP $19.25
- ATAI $65.58
- Revenue Next Year
- DSP $16.72
- ATAI N/A
- P/E Ratio
- DSP $104.97
- ATAI N/A
- Revenue Growth
- DSP 30.64
- ATAI N/A
- 52 Week Low
- DSP $8.62
- ATAI $1.03
- 52 Week High
- DSP $26.33
- ATAI $2.57
- Technical
- Relative Strength Index (RSI)
- DSP 53.53
- ATAI 44.57
- Support Level
- DSP $12.58
- ATAI $1.36
- Resistance Level
- DSP $15.31
- ATAI $1.54
- Average True Range (ATR)
- DSP 0.83
- ATAI 0.09
- MACD
- DSP 0.14
- ATAI -0.00
- Stochastic Oscillator
- DSP 73.10
- ATAI 0.00
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.